Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings. A systematic process for exclusion of alternative diagnoses has not been defined. An International Panel of MS experts developed consensus perspectives on MS differential diagnosis.
Methods
Using available literature and consensus, we developed guidelines for MS differential diagnosis, focusing on exclusion of potential MS mimics, diagnosis of common initial isolated clinical syndromes, and differentiating between MS and non-MS idiopathic inflammatory demyelinating diseases.
Results
We present recommendations for 1) clinical and paraclinical red flags suggesting alternative diagnoses to MS; 2) more precise definition of “clinically isolated syndromes” (CIS), often the first presentations of MS or its alternatives; 3) algorithms for diagnosis of three common CISs related to MS in the optic nerves, brainstem, and spinal cord; and 4) a classification scheme and diagnosis criteria for idiopathic inflammatory demyelinating disorders of the central nervous system.
Conclusions
Differential diagnosis leading to MS or alternatives is complex and a strong evidence base is lacking. Consensus-determined guidelines provide a practical path for diagnosis and will be useful for the non-MS specialist neurologist. Recommendations are made for future research to validate and support these guidelines. Guidance on the differential diagnosis process when MS is under consideration will enhance diagnostic accuracy and precision.
1 Schumacher FA Beeve GW Kibler FR . Problems of experimental trials of therapy in multiple sclerosis . Ann NY Acad Sci1965; 122: 552 – 568 .
2.
2 Poser CM Paty DW Scheinberg LC . New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol1983; 13: 227 – 231 .
3.
3 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis . Ann Neurol2001; 50: 121 – 127 .
4.
4 Polman CH Reingold SC Edan G . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” . Ann Neurol2005; 58: 840 – 846 .
5.
5 Charil A Yousry TA Rovaris M . MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation” . Lancet Neurol2006; 5: 841 – 852 .
6.
6 Jacobs LD Beck RW Simon JH . Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group . N Engl J Med2000; 343: 898 – 904 .
7.
7 Comi G Filippi M Barkhof F . Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study . Lancet2001; 357: 1576 – 1582 .
8.
8 Kappos L Polman CH Freedman MS . Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes . Neurology2006; 10: 1242 – 1249 .
9.
9 Swanton JK Rovira A Tintoré M . MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study . Lancet Neurol2007; 6: 677 – 686 .
10.
10 Ormerod IE Miller DH McDonald WI . The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study . Brain1987; 110: 1579 – 1616 .
11.
11 Uitdehaag BMJ Kappos L Bauer L . Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of MS: a proposal for standardization . Mult Scler2005; 11: 227 – 231 .
12.
12 Mastronardo G Rocca MA Iannucci G Pereira C Filippi M . A longitudinal MR study of the presymptomatic phase in a patient with clinically definite multiple sclerosis . Am J Neuroradiol1999; 20: 1268 – 1272 .
13.
13 Brex PA Ciccarelli O O’Riordan JI Sailer M Thompson AJ Miller DH . A longitudinal study of abnormalities on MRI and disability from multiple sclerosis . N Engl J Med2002; 246: 158 – 164 .
14.
14 Minneboo A Barkhof F Polman CH Uitdehaag BM Knol DL Castelijns JA . Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis . Arch Neurol2004; 61: 217 – 221 .
15.
15 Optic Neuritis Study Group . Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis . Arch Neurol2004; 61: 1538 – 1541 .
16.
16 Tintoré M Rovira A Rio J . Baseline MRI predicts future attacks and disability in clinically isolated syndromes . Neurology2006; 67: 968 – 972 .
17.
17 Kangarlu A Bourekas EC Ray-Chaudhury A Rammohan KW . Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla . Am J Neuroradiol2007; 28: 262 – 266 .
18.
18 Lebrun C Bensa C Debouverie M . Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile . J Neurol Neurosurg Psychiatry2008; 79: 195 – 198 .
19.
19 Wingerchuk DM Lennon VA Pittock SJ Lucchinetti CF Weinshenker BG . Revised diagnostic criteria for neuromyelitis optica . Neurology2006; 66: 1485 – 1489 .
20.
20 Saiz A Zuliani L Blanco Y . Revised diagnostic criteria for neuromyelitis optica: application in a series of suspected patients . J Neurol2007; 254: 1233 – 1237 .
21.
21 Cohen O Steiner-Birmanns B Biran I Abramsky O Honigman S Steiner I . Recurrence of acute disseminated encephalomyelitis at the previously affected brain site . Arch Neurol2001; 58: 797 – 701 .
22.
22 Hartung HP Grossman RI . ADEM: distinct disease or part of the MS spectrum . Neurology2001; 56: 1257 – 1260 .
23.
23 Anlar B Basaran C Kose G . Acute disseminated encephalomyelitis in children: outcome and prognosis . Neuropediatrics2003; 24: 194 – 199 .
24.
24 Morimatsu M . Recurrent ADEM or MS . Int Med2004; 43: 647 – 648 .
25.
25 Jacob A Matiello M Wingerchuk DM Lucchinetti CF Pittock SJ Weinshenker BG . Neuromyelitis optica: changing concepts . J Neuroimmunol2007; 187: 126 – 138 .
26.
26 Wingerchuk DM Lennon VA Lucchinetti CF Pittock SJ Weinshenker BG . The spectrum of neuromyelitis optica . Lancet Neurol2007; 6: 805 – 815 .
27.
27 O’Riordan JI Gallagher HL Thompson AJ . Clinical, CSF and MRI findings in Devic’s neuromyelitis optica . J Neurol Neurosurg Psychiatry1996; 60: 382 – 387 .
28.
28 Wingerchuk DM Hogancamp WF O’Brien PC Weinshenker BG . The clinical course of neuromyelitis optica (Devic’s syndrome) . Neurology1999; 53: 1107 – 1114 .
30 de Seze J Lebrun C Stojkovic T Ferriby D Chatel M Vermersch P . Is Devic’s neuromyelitis optica a separate disease? A comparative study with multiple sclerosis . Mult Scler2003; 9: 521 – 525 .
31.
31 Ghezzi A Bergamaschi R Martinelli V . Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica . J Neurol2004; 251: 47 – 52 .
32.
32 Lennon VA Wingerchuk DM Kryzer TJ . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis . Lancet2004; 364: 2106 – 2112 .
33.
33 Jarius S Franciotta D Bergamaschi R . NMO-IgG in the diagnosis of neuromyelitis optica . Neurology2007; 68: 1076 – 1077 .
34.
34 Keegan M Pineada AA McClelland RL Darby CH Rodriguez M Weinshenker BG . Plasma exchange for severe attacks of CNS demyelination: predictors of response . Neurology2003; 58: 143 – 146 .
35.
35 Papeix C Vidal JS de Seze J . Immunosuppressive therapy is more effective than interferon in neuromyelitis optica . Mult Scler2007; 13: 256 – 259 .
36.
36 Warabi Y Matsumoto Y Hayashi H . Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination . J Neurol Sci2007; 252: 257 – 261 .
37.
37 Mandler RN Davis LE Jeffery DR Kornfeld M . Devic’s neuromyelitis optica: a clinicopathological study of 8 patients . Ann Neurol1993; 34: 162 – 168 .
38.
38 Filippi M Rocca MA Moiola L . MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic’s neuromyelitis optica . Neurology1999; 53: 1705 – 1710 .
39.
39 Rocca MA Agosta F Mezzapesa DM . Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica . Neurology2004; 10: 476 – 478 .
40.
40 Barkhof F Filippi M Miller DH . Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis . Brain1997; 120: 2059 – 2069 .
41.
41 Pittock SJ Lennon VA Wingerchuk DM Lucchinetti CF Weinshenker BG . Brain abnormalities in neuromyelitis optica . Arch Neurol2006; 63: 390 – 396 .
42.
42 Pittock SJ Weinshenker GB Lucchinetti CF Wingerchuk DM Corboy JR Lennon VA . Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression . Arch Neurol2006; 63: 964 – 968 .
43.
43 Bergamaschi R Tonietti S Franciotta D . Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis. Differences in repeated cerebrospinal fluid examinations . Mult Scler2004; 10: 2 – 4 .
44.
44 Weinshenker BG Wingerchuk DM Vukusic S . Neuromyelitis optica IgG predicts relapse after longitudinal extensive transverse myelitis . Ann Neurol2006; 59: 566 – 569 .
45.
45 Matiello M Lennon VA Jacopb A . NMO-IgG predicts the outcome of recurrent optic neuritis . Neurology2008; 70: 2197 – 2220 .
46.
46 Pittock SJ Lennon VA de Seze J . Neuromyelitis optica and non-organ-specific autoimmunity . Arch Neurol2008; 65: 78 – 83 .
47.
47 Kira J . Multiple sclerosis in the Japanese population . Lancet Neurol2003; 2: 117 – 127 .
48.
48 Matsuoka T Matsushita T Kawano Y . Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese . Brain2007; 130: 1206 – 1223 .
49.
49 Kesselring J Miller DH Robb SA . Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis . Brain1990; 113: 291 – 302 .
50.
50 de Seze J Debouverie M Zephir H . Acute fulminant demyelinating disease: a descriptive study of 60 patients . Arch Neurol2007; 64: 1426 – 1432 .
51.
51 Banwell B Shroff M Ness JM . MRI features of pediatric multiple sclerosis . Neurology2007; 68(Suppl. 2): S46 – S53 .
52.
52 Krupp LB Banwell B Tenembaum S . for the International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders . Neurology2007; 68(Suppl. 2): S7 – S12 .
53.
53 Brinar VV Poser CM . The spectrum of disseminated encephalomyelitis . Clin Neurol Neurosurg2006; 108: 2295 – 2310 .
54.
54 Lublin FD Reingold SC . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . Neurology1996; 40: 469 – 479 .
55.
55 Mendez MF Pogacar S . Malignant monophasic multiple sclerosis or “Marburg’s disease”.Neurology1988; 38: 1153 – 1155 .
56.
56 Johnson MD Lavin P Whetsell WO . Fuminant monophasic multiple sclerosis, Marburg’s type . J Neurol Neurosurg Psychiatry1990; 53: 918 – 921 .
57.
57 Moore GR Neumann PE Suzuki K Lijtmaer HN Traugott U Raine CS . Balo’s concentric sclerosis: new observations on lesion development . Ann Neurol1985; 17: 604 – 611 .
59 Kepes J . Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis: a study of 31 patients . Ann Neurol1993; 22: 18 – 27 .
60.
60 Morrissey SP Miller DH Kendall BE . The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study . Brain1993; 116: 135 – 146 .
61.
61 Söderström M Ya-Ping J Hillert J Link H . Optic neuritis. Prognosis for multiple sclerosis from MRI, CSF and HLA findings . Neurology1998; 50: 708 – 714 .
62.
62 Weinshenker BG Gilbert JJ Ebers GC . Some clinical and pathologic observations on chronic myelopathy: a variant of multiple sclerosis . J Neurol Neurosurg Psychiatry1990; 53: 146 – 149 .
